Immunomodulatory Therapy for Giant Cell Myocarditis: A Narrative Review

Area of Science:

• Cardiology and Immunology

Background:

• Giant cell myocarditis (GCM) is a rare, aggressive, and potentially fatal inflammatory heart disease.
• It affects all ages but is more prevalent in adults and certain ethnic groups, necessitating early diagnosis and intervention.

Purpose of the Study:

• To review diagnostic tools and treatment strategies for Giant Cell Myocarditis.
• To emphasize the critical role of immunosuppressive therapy in improving patient outcomes.

Main Methods:

• Diagnostic approaches include electrocardiogram (EKG), cardiac biomarkers (troponin, BNP), imaging (echocardiogram, MRI), and myocardial biopsy.
• Therapeutic strategies focus on immunosuppression, including corticosteroids and immunomodulatory agents like rituximab, cyclosporine, and infliximab.

Main Results:

• Immunosuppressive therapy is crucial; without it, mortality or cardiac surgery rates approach 100%.
• Combination therapy (corticosteroids plus immunomodulatory agents) demonstrates superior efficacy over corticosteroids alone.
• Combination therapy significantly enhances transplant-free survival (TFS) and reduces the need for heart transplantation.

Conclusions:

• Immunomodulatory therapy provides substantial long-term survival benefits for GCM patients.
• Balancing the benefits of immunosuppression against potential adverse effects is essential for optimal patient management.